Biochimica et Biophysica Acta (BBA) - Biomembranes
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Abstract
Chinese hamster ovary cells selected for resistance to colchicine display pleiotropic cross-resistance to a wide range of amphiphilic drugs. The drug-resistant phenotype is due to a membrane alteration which reduces the rate of drug permeation. Surface labelling studies reveal that drug-resistant Chinese hamster ovary cell membranes possess a carbohydrate-containing component of 170 000 daltons apparent molecular weight which is not observed in wild type cells. Through studies of the metabolic incorporation of carbohydrate and protein precursors, and through the use of selective proteolysis, this component is shown to be a cell surface glycoprotein. Since this glycoprotein appears unique to mutant cells displaying altered drug permeability, we have designated it the glycoprotein. The relative amount of surface labelled glycoprotein correlates with the degree of drug resistance in a number of independent mutant and revertant clones. A similar high molecular weight glycoprotein is also present in drug-resistant mutants from another hamster cell line. Observations on the molecular basis of pleiotropic drug resistance are interpreted in terms of a model wherein certain surface glycoproteins control drug permeation by modulating the properties of hydrophobic membrane regions.
References (22)
- Y.P. See et al.
Biochim. Biophys. Acta
(1974) - R.L Juliano et al.
Biochim. Biophys. Acta
(1975) - M. McBurney et al.
Cell
(1974) - R.L. Juliano et al.
Biochim. Biophys. Acta
(1975) - H.B. Bosmann et al.
Arch. Biochem. Biophys.
(1969) - T.L Steck et al.
J. Biol. Chem.
(1974) - C.G. Gahmberg et al.
J. Biol. Chem.
(1975) - V. Ling et al.
J. Cell. Physiol.
(1974) - V. Ling
Can. J. Genet. Cytol.
(1975) - N.T. Bech Hansen et al.
J. Cell Physiol.
(1976)
Biochim. Biophys. Acta
Cited by (2995)
The prevention of multi-drug resistance in cancers through the application of nanotechnology-based targeted delivery systems for combination therapies involving traditional Chinese medicine
2024, Pharmacological Research - Modern Chinese MedicineThe most significant obstacle in addressing cancer is the development of multidrug resistance during chemotherapy. Cancer cells have the ability to endure numerous cycles of traditional chemotherapy drugs before ultimately developing resistance to the treatment. Combining drugs is a strategy used to address the problem of multidrug resistance. Persistent challenges with synthetic drugs include catastrophic adverse reactions and other consequences. Natural compounds originating from traditional Chinese medicine are acknowledged for their minimal toxicity and possible benefits in reversing multidrug resistance induced by mainstream chemotherapeutic or targeted treatments. Cancer multidrug resistance (MDR) is an immediate clinical justification for unsatisfactory chemotherapy treatment. Cancer recurrence and metastasis are precipitated by MDR, leading to a high risk of death. The development of a unique nano-delivery method for the therapeutic management of MDR cancers has emerged as a key use of nanotechnology. Because of its significant anticancer prospective, traditional Chinese medicine (TCM)-combination therapy is an emerging treatment modality and an essential treatment option for cancer. By precisely regulating the release of medicines and delivering pharmaceuticals to cancerous cells, nano targeted drug-delivery devices offer amazing benefits and pave the way for the growth of TCM-combination therapies.
The present review examines the literature on three important topics: the mechanism of MDR in cancer chemotherapy, the role of traditional Chinese herbs and formulation in MDR treatment, and the incorporation of TCM in nanotechnology-based drug delivery systems to circumvent the limitations of traditional system. Major sources for the work include PubMed, Google Scholar, ResearchGate, Embase, and ScienceDirect. All the aspects pertaining to MDR, TCM, and nanotechnology for more than 50 years were considered, with an emphasis on the use of TCM in nano formulation, various forms of nano formulation, advances in the drug delivery system as a result of nanotechnology, and everything else in between.
As nanotechnology becomes more closely associated with TCM, the realm of practice for TCM is broadening. Furthermore, it enhances the prospects for future research and facilitates the advancement of modern Traditional Chinese Medicine (TCM). By integrating nanotechnology into a meticulously designed drug delivery system, TCM will enhance its ability to both treat and prevent diseases with even greater efficacy than previously.
This article examines nano-TCM and explores its characteristics, compositions, and relevant techniques for preparation and application in reversing MDR. In addition, a comprehensive elucidation of the key benefits of nano-TCM had been given with respect to MDR. The objective of this study was to analyze the existing body of literature on the application of nanotechnology in traditional Chinese medicine (TCM) that can be used in the treatment of MDR. The review encompasses various aspects like the development of active components for TCM, the utilization of TCM for reversing multidrug resistance (MDR), and the potential future advancements and obstacles associated with TCM-based nano combinations.
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy
2024, Drug Resistance UpdatesMultidrug resistance (MDR) is one of the primary factors that produces treatment failure in patients receiving cancer chemotherapy. MDR is a complex multifactorial phenomenon, characterized by a decrease or abrogation of the efficacy of a wide spectrum of anticancer drugs that are structurally and mechanistically distinct. The overexpression of the ATP-binding cassette (ABC) transporters, notably ABCG2 and ABCB1, are one of the primary mediators of MDR in cancer cells, which promotes the efflux of certain chemotherapeutic drugs from cancer cells, thereby decreasing or abolishing their therapeutic efficacy. A number of studies have suggested that non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play a pivotal role in mediating the upregulation of ABC transporters in certain MDR cancer cells. This review will provide updated information about the induction of ABC transporters due to the aberrant regulation of ncRNAs in cancer cells. We will also discuss the measurement and biological profile of circulating ncRNAs in various body fluids as potential biomarkers for predicting the response of cancer patients to chemotherapy. Sequence variations, such as alternative polyadenylation of mRNA and single nucleotide polymorphism (SNPs) at miRNA target sites, which may indicate the interaction of miRNA-mediated gene regulation with genetic variations to modulate the MDR phenotype, will be reviewed. Finally, we will highlight novel strategies that could be used to modulate ncRNAs and circumvent ABC transporter-mediated MDR.
P-glycoprotein (Pgp) is a member of the ATP-binding cassette family of transporters that confers multidrug resistance to cancer cells and is actively involved in the pharmacokinetics and toxicokinetics of a big variety of drugs. Extensive studies have provided insights into the binding of many compounds, but the precise mechanism of translocation across the membrane remains unknown; in this context, the major challenge has been to understand the basis for its polyspecificity. In this study, molecular dynamics (MD) simulations of human P-gp (hP-gp) in an explicit membrane-and-water environment were performed to investigate the dynamic behavior of the transporter in the presence of different compounds (active and inactive) in the binding pocket and ATP molecules within the nucleotide binding domains (NBDs). The complexes studied involve four compounds: cyclosporin A (CSA), amiodarone (AMI), pamidronate (APD), and valproic acid (VPA). While CSA and AMI are known to interact with P-gp, APD and VPA do not. The results highlighted how the presence of ATP notably contributed to increased flexibility of key residues in NBD1 of active systems, indicating potential conformational changes activating the translocation mechanism. MD simulations reveal how these domains adapt and respond to the presence of different substrates, as well as the influence of ATP binding on their flexibility. Furthermore, distinctive behavior was observed in the presence of active and inactive compounds, particularly in the arrangement of ATP between NBDs, supporting the proposed nucleotide sandwich dimer mechanism for ATP binding. This study provides comprehensive insights into P-gp behavior with various ligands and ATP, offering implications for drug development, toxicity assessment and demonstrating the validity of the results derived from the MD simulations.
Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment
2024, Biochimica et Biophysica Acta - Molecular Basis of DiseaseThe blood-brain-barrier (BBB) has a major function in maintaining brain homeostasis by regulating the entry of molecules from the blood to the brain. Key players in BBB function are BBB transporters which are highly expressed in brain endothelial cells (BECs) and critical in mediating the exchange of nutrients and waste products. BBB transporters can also influence drug delivery into the brain by inhibiting or facilitating the entry of brain targeting therapeutics for the treatment of brain disorders, such as Alzheimer's disease (AD). Recent studies have shown that AD is associated with a disrupted BBB and transporter dysfunction, although their roles in the development in AD are not fully understand. Modulation of BBB transporter activity may pose a novel approach to enhance the delivery of drugs to the brain for enhanced treatment of AD. In this review, we will give an overview of key functions of BBB transporters and known changes in AD. In addition, we will discuss current strategies for transporter modulation for enhanced drug delivery into the brain.
Progress in characterizing ABC multidrug transporters in zebrafish
2024, Drug Resistance UpdatesZebrafish have proved to be invaluable for modeling complex physiological processes shared by all vertebrate animals. Resistance of cancers and other diseases to drug treatment can occur owing to expression of the ATP-dependent multidrug transporters ABCB1, ABCG2, and ABCC1, either because of expression of these transporters by the target cells to reduce intracellular concentrations of cytotoxic drugs at barrier sites such as the blood-brain barrier (BBB) to limit penetration of drugs into privileged compartments, or by affecting the absorption, distribution, and excretion of drugs administered orally, through the skin, or directly into the bloodstream. We describe the drug specificity, cellular localization, and function of zebrafish orthologs of multidrug resistance ABC transporters with the goal of developing zebrafish models to explore the physiological and pathophysiological functions of these transporters. Finally, we provide context demonstrating the utility of zebrafish in studying cancer drug resistance. Our ultimate goal is to improve treatment of cancer and other diseases which are affected by ABC multidrug resistance transporters.
Kinetic modelling of the P-glycoprotein mediated efflux with a large-scale matched molecular pair analysis
2023, European Journal of Medicinal ChemistryP-glycoprotein (Pgp) mediated efflux impacts on the drug absorption, distribution, metabolism and excretion, and confers multidrug resistance to cancer cells. Kinetic modelling provides mechanistic insights into the relationship between the substrate-Pgp interactions and efflux, and bridges the gap between the preference of polar compounds as Pgp substrates and the hydrophobic nature of its drug-binding site. Matched molecular pair analysis supports the guidelines of controlling H-bond donors and polar surface area in the efflux mitigation, but also reveals insufficiency of this type of rule-based approach. Contrary to the rule-of-five compliant compounds, proteolysis-targeting chimeras (PROTACs) have shown the opposite preference of physicochemical properties to evade efflux. Our analysis reiterates the critical role of intrinsic passive permeability in the efflux ratio, and indeed, its mitigation is often driven by increased passive permeability. It is thus useful to separate the passive permeability from the structural context-specific substrate-Pgp interactions in the design cycle.